Conor Killmurray | Authors

Liso-Cel Leads to Durable Responses in Second-Line Therapy in Relapsed/Refractory LBCL

June 05, 2022

The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.

Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHN

March 02, 2022

Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.